Creatinine / eGFR
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- eGFR above 90 is the longevity-optimal target. The standard threshold of 60 identifies advanced kidney disease — by the time eGFR falls below 90, years of subclinical decline have typically already occurred.
- Track the trend, not just the number. A single eGFR of 80 is less informative than knowing whether it has been stable at 80 or declining from 95 over 5 years. Trajectory is the critical signal.
- Declining kidney function dramatically accelerates cardiovascular disease. Even mild CKD (eGFR 60–90) is an independent cardiovascular risk factor roughly equivalent to having diabetes.
- Creatinine is muscle-mass dependent. A muscular person can have a 'high' creatinine with excellent kidney function; a frail elderly person can have a 'normal' creatinine with severely impaired function. eGFR corrects for this but still has limitations.
- Early kidney protection is highly actionable. Blood pressure control, optimal glycemic health, avoiding NSAIDs and nephrotoxic medications, hydration, and optimizing uric acid are the primary interventions.
The Kidneys as Longevity Organs: Why Function Matters More Than Most People Think
The kidneys are rarely discussed in longevity medicine conversations dominated by cardiovascular health, metabolic function, and hormonal optimization. This is a significant oversight. Kidney function decline is one of the most powerful independent predictors of cardiovascular mortality and all-cause mortality, operating through mechanisms that directly amplify aging across multiple organ systems simultaneously.
The kidneys perform functions that extend far beyond waste filtration. They regulate blood pressure through the renin-angiotensin-aldosterone system, control red blood cell production via erythropoietin, maintain bone mineral density through vitamin D activation, regulate acid-base balance, control electrolyte concentrations that determine cardiac and neurological function, and clear hundreds of waste products, toxins, and metabolites that accumulate with cellular metabolism. When kidney function declines, each of these regulatory functions is impaired in proportion.
What makes kidney function particularly important from a longevity perspective is the timeline. Kidney damage accumulates silently for years or decades before eGFR falls below clinical thresholds. By age 40, most adults have already experienced some age-related decline. By the time eGFR crosses below 60 — the conventional clinical alarm — patients are typically 20–30 years into a decline that began with largely preventable risk factors: hypertension, insulin resistance, elevated uric acid, chronic NSAID use, and dehydration.
Understanding the CKD Staging System and Its Limitations
Chronic kidney disease (CKD) is staged by eGFR, which provides a useful framework for tracking decline over time.
| CKD Stage | eGFR (mL/min/1.73m²) | Description | Longevity Assessment |
|---|---|---|---|
| None | > 90 | Normal or high | Optimal — target range for longevity |
| Stage 1 | 60–89 (with damage markers) | Mildly reduced | Monitor — early decline; address modifiable causes |
| Stage 2 | 45–59 | Mildly to moderately reduced | Elevated risk — cardiovascular risk rising; nephrology evaluation |
| Stage 3 | 30–44 | Moderately reduced | High risk — significant cardiovascular and progression risk |
| Stage 4–5 | < 30 | Severely reduced / failure | Very high risk — specialist management required |
From a longevity perspective, the critical insight is that the standard "no CKD" classification (eGFR above 60) includes a wide range of kidney health. An eGFR of 62 and an eGFR of 110 are both technically "normal" — but the cardiovascular and mortality risk profiles are dramatically different. This is why the longevity-optimal target is above 90, not simply above 60.
More important than any single value is the trajectory. A five-year decline from eGFR 98 to 85 — both technically "normal" — represents a rate of loss (-2.6 mL/min/year) that, if sustained, will reach CKD stage 2 within two decades. The normal age-related decline is roughly 1 mL/min/year after age 40 — faster decline demands investigation of modifiable causes.
Already have your lab results? See how your creatinine and eGFR and other markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →Creatinine and Its Limitations: The Muscle Mass Problem
Serum creatinine is a useful but imperfect kidney marker because it is confounded by muscle mass. Creatinine is produced by the breakdown of creatine phosphate in muscle tissue — a process that occurs at a rate proportional to total muscle mass. A highly muscular person generates more creatinine per day, resulting in higher serum creatinine for any given level of kidney function. A person with very low muscle mass generates less creatinine, resulting in lower serum creatinine even if kidney function is significantly impaired.
This is why interpreting creatinine requires context. A male athlete with a serum creatinine of 1.4 mg/dL may have excellent kidney function — the high creatinine reflects high muscle mass, not poor filtration. An elderly woman with a creatinine of 0.9 mg/dL might have substantially impaired kidney function if her muscle mass is very low — the "normal" creatinine reflects inadequate creatinine production, not good clearance.
eGFR partially corrects for this by adjusting for age and sex — both of which correlate with typical muscle mass. But the correction is imperfect for outliers. In individuals where accuracy is critical — particularly very muscular people or very frail older adults — cystatin C provides a better eGFR estimate. Cystatin C is a protein filtered by the kidneys at a constant rate independent of muscle mass, and it is increasingly available on standard panels.
Protecting Kidney Function: The Highest-Leverage Interventions
The kidneys are highly sensitive to several modifiable risk factors, and addressing them earlier rather than later produces the greatest long-term benefit.
- Blood pressure control: Hypertension is the leading cause of kidney disease progression. The intraglomerular pressure required to filter blood through damaged kidneys accelerates further damage — a vicious cycle that blood pressure control directly interrupts. Target below 120/80 mmHg for optimal kidney protection; ACE inhibitors and ARBs have specific renoprotective effects beyond their blood pressure-lowering action.
- Glycemic optimization: Diabetic nephropathy is the most common cause of end-stage renal disease in developed countries. Maintaining HbA1c below 5.5% and fasting insulin below 6 µIU/mL minimizes the glucose-driven glomerular hyperfiltration and mesangial expansion that initiates diabetic kidney injury.
- Uric acid reduction: Elevated uric acid causes afferent arteriolar vasoconstriction and direct tubular toxicity. Targeting uric acid below 5.5 mg/dL through dietary changes (primarily fructose and alcohol reduction) protects kidney function independently of its cardiovascular benefits.
- NSAID avoidance: NSAIDs (ibuprofen, naproxen, aspirin at high doses) impair renal prostaglandin synthesis, reducing renal blood flow and GFR. Chronic NSAID use is a major and underrecognized cause of progressive kidney disease. Acetaminophen is significantly safer for the kidneys when pain relief is needed.
- Adequate hydration: Chronic mild dehydration concentrates waste products and reduces tubular flow, increasing exposure of the tubular epithelium to potentially nephrotoxic solutes. Targeting light yellow urine throughout the day is a simple hydration adequacy proxy.
- Protein intake calibration: Very high protein intake (above 2.5–3.0 g/kg/day) increases glomerular filtration pressure and may accelerate kidney function decline in people with pre-existing kidney disease. In healthy individuals, protein at 1.6–2.2 g/kg/day appears safe — but if eGFR is declining, protein intake warrants monitoring.
How to Test and When
Creatinine and eGFR are included in the comprehensive metabolic panel (CMP) or basic metabolic panel (BMP) available at any standard laboratory. No fasting is required, though heavy exercise in the preceding 24–48 hours can transiently raise creatinine by increasing muscle breakdown — a clinically minor but measurable effect.
Annual testing as part of a comprehensive metabolic panel is appropriate for most adults. If you have risk factors for kidney disease (hypertension, diabetes, family history of kidney disease, recurrent kidney stones, chronic NSAID use), testing every 6 months and tracking the trend over time is worthwhile.
Always record the absolute eGFR values from year to year and calculate the annual rate of change. A stable eGFR over 5–10 years is reassuring. A consistent downward trend — even within the "normal" range — warrants investigation of modifiable causes before the trajectory becomes harder to reverse.
For the most complete kidney health picture alongside creatinine and eGFR: add uric acid (a driver of kidney damage), albumin (a marker of tubular health and protein nutrition), BUN (blood urea nitrogen, which provides a filtration cross-check), and a urine microalbumin-to-creatinine ratio (which detects early diabetic or hypertensive kidney damage before eGFR changes).
Sources
- Go AS, et al. "Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization." New England Journal of Medicine, 2004. PubMed →
- Levey AS, Stevens LA. "Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation." Annals of Internal Medicine, 2011. PubMed →
| Range Type | Value (mg/dL (creatinine) · mL/min/1.73m² (eGFR)) | Notes |
|---|---|---|
| Standard Clinical Range | Creatinine: 0.7–1.2 mg/dL (men), 0.5–1.0 mg/dL (women) · eGFR: > 60 mL/min/1.73m² | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | Creatinine: 0.7–1.0 mg/dL · eGFR: > 90 mL/min/1.73m² |
Associated with reduced all-cause mortality and extended healthspan.
The standard threshold of eGFR > 60 identifies the onset of chronic kidney disease (CKD) stage 3. For longevity optimization, maintaining eGFR above 90 is the target — and tracking the trajectory over time is as important as any single value. A steady decline of 5+ mL/min/year is concerning regardless of the absolute eGFR.
|
Already have your results? See what your Creatinine / eGFR and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
What is a good eGFR for longevity?
The longevity-optimal eGFR is above 90 mL/min/1.73m². This is the level associated with fully preserved kidney function. The standard clinical threshold for concern is eGFR below 60, which marks stage 3 chronic kidney disease — by which point meaningful kidney damage has typically accumulated over years. From a longevity perspective, the target is to maintain eGFR well above 90 and to monitor for decline over time. eGFR naturally declines about 1 mL/min/year after age 40 — making it normal to see declining values with age. The longevity question is whether the rate of decline is within the expected age-related range or accelerated by modifiable risk factors.
Why is creatinine alone insufficient to assess kidney function?
Creatinine production is proportional to muscle mass, not just kidney function. A 25-year-old male bodybuilder with 220 lbs of muscle mass will produce significantly more creatinine daily than a 75-year-old woman with 110 lbs of muscle mass. If both have impaired kidney function, the bodybuilder's creatinine might be 1.8 mg/dL while the elderly woman's is 1.0 mg/dL — but the woman's kidney function might be substantially worse. eGFR corrects for age and sex differences in muscle mass, giving a more accurate estimate of filtration capacity across different body types. However, eGFR is still an estimate. In extreme cases (very muscular athletes, sarcopenic older adults, people eating very high or very low protein diets), eGFR may under- or over-estimate actual kidney function. Cystatin C is an alternative filtration marker that is independent of muscle mass and may provide a more accurate eGFR estimate in these populations.
How does declining kidney function accelerate cardiovascular disease?
The kidney–heart connection operates through multiple mechanisms. As kidney function declines, fluid and sodium retention raises blood pressure — the most consistent cardiovascular risk factor. Accumulating uremic toxins (waste products not adequately cleared by damaged kidneys) directly damage the vascular endothelium, accelerate atherosclerosis, and promote vascular calcification. Declining kidney function is associated with anemia (reduced erythropoietin production), which forces the heart to work harder to deliver oxygen. Disrupted phosphate and calcium metabolism from kidney disease promotes calcification of arteries and heart valves. All of these mechanisms operate continuously in a reinforcing cycle: kidney disease worsens cardiovascular health, and cardiovascular disease (particularly hypertension and atherosclerosis) further damages the kidneys.
What are the main causes of accelerated kidney function decline?
The leading causes of accelerated kidney function decline are hypertension (the most common cause of kidney disease in developed countries), type 2 diabetes and insulin resistance, elevated uric acid (which causes both tubular damage and afferent arteriolar vasoconstriction), chronic use of NSAIDs (ibuprofen, naproxen — which impair renal blood flow), dehydration (particularly chronic low fluid intake), recurrent urinary tract infections, and some medications including certain antibiotics and contrast agents used in imaging. Genetic factors also play a significant role — variants in APOL1 (common in people of African ancestry) confer substantially elevated risk of kidney disease progression.
What is the difference between eGFR and GFR?
GFR (glomerular filtration rate) is the true gold standard measure of kidney function — the actual volume of blood filtered by the kidneys per minute per 1.73 m² of body surface area. Measuring true GFR requires injecting a filtration marker (typically inulin or iohexol) and precisely tracking its clearance — a time-consuming and expensive procedure used primarily in research. eGFR (estimated GFR) uses serum creatinine along with age, sex, and race (in some equations) to estimate filtration capacity using validated mathematical equations. The CKD-EPI equation is the current clinical standard. eGFR is a reliable estimate for most people in the normal-to-moderately-reduced range but becomes less accurate at very high or very low GFR values and in populations with unusual muscle mass.